Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy
Atezolizumab was not considered cost-effective at the WTP thresholds of $150,000 per QALY in the US and $36,024 per QALY in China for patients with advanced NSCLC who are ineligible for platinum-based chemotherapy.
Authors
- Qiuji Wu (ORCID: https://orcid.org/0000-0001-9205-4193)
- Qiu Li
- Qin Yi (ORCID: https://orcid.org/0000-0003-0086-5912)
Institutions
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3389/fpubh.2025.1349645
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- China Postdoctoral Science Foundation